BioNTech (BNTX)
(Delayed Data from NSDQ)
$94.10 USD
-2.85 (-2.94%)
Updated May 28, 2024 04:00 PM ET
After-Market: $94.11 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
BioNTech SE Sponsored ADR [BNTX]
Reports for Purchase
Showing records 141 - 154 ( 154 total )
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
BNT162b1 and BNT162b2 Receive Fast Track Designation; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
BNT162b1 Demonstrates Encouraging Early Immunogenicity; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
Recent Stock Appreciation Raises Risk Profile; Downgrade to Neutral Without PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
We See Increased Risk for RO7198457 in 1L Melanoma; Lowering to $63
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
BNT162 Read Through From Competing Vaccine Data; Upgrading to Buy and $69 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
BNT162 COVID-19 Vaccine Phase 1/2 Initial Cohort Dosing Completion; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
German Regulatory Authorization for BNT162 Phase 1/2 Trial; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
We See Potential Upside to Our BNT162 Forecasts; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
BNT162 and BNT151 Added to Forecasts; Reiterate Neutral; Raising PT to $48
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
2019 Financials; COVID-19 Impact on Clinical Programs; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
COVID-19 Vaccine Candidate Program Announced; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
Teutonic Technical Precision at a Hefty Price Tag; Initiating at Neutral and $30 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R